← Leaderboards
Darren G Woodside
Texas Heart Institute
$3,775,052
Attributed
$7,862,696
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2012–25$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,862,696 · 9
By mechanism
R42$3,997,722 · 2
R61$1,128,631 · 1
R01$1,124,550 · 1
R41$853,711 · 3
R33$534,347 · 1
R43$223,735 · 1
Top collaborators
- Ronald J Biediger5 shared
- Upendra Marathi4 shared
- George Holland3 shared
- Yared Hailemichael2 shared
- Heather Giles1 shared
- Willem W Overwijk1 shared
Most similar at Texas Heart Institute
Same institution · by research overlap
- Ronald J Biediger$2,043,958
Others in their field
Top investigators on “Integrins”
- Timothy A Springer · Boston Children'S Hospital$50,095,849
- David A Cheresh · Scripps Research Institute$28,587,859
- Mark Howard Ginsberg · University Of California, San Diego$28,221,483
- Martin A. Schwartz · Yale University$23,274,443
- M. Amin Arnaout · Massachusetts General Hospital$23,064,887
- Edward Franklin Plow · Cleveland Clinic Foundation$22,902,830
Research focus
IntegrinsCellsFutureSmall MoleculeLeadResponsePharmaceutical PreparationsIn VivoDoseSafetyPlayDrug KineticsInflammatoryCell Adhesion MoleculesPropertyPharmacologic SubstanceClinical TrialsProgramsMouse ModelReceptorNovel StrategiesBaseDrug CandidateDesign
Grant awards (14)
Targeting Integrin Signaling in Atherosclerosis$534,347
R33 · FY2025 · HL · contact PI
Selective targeting of high affinity alpha4 integrins as a safe treatment strategy for IBD$959,682
R42 · FY2024 · DK · contact PI
Targeting Integrin Signaling in Atherosclerosis$556,549
R61 · FY2024 · HL · contact PI
Selective targeting of high affinity alpha4 integrins as a safe treatment strategy for IBD$1,036,641
R42 · FY2023 · DK · contact PI
Targeting Integrin Signaling in Atherosclerosis$572,082
R61 · FY2023 · HL · contact PI
Selective targeting of high affinity alpha4 integrins as a safe treatment strategy for IBD$296,724
R41 · FY2020 · DK · contact PI
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer$1,001,898
R42 · FY2019 · CA
Integrin Activation as a Treatment for Leukocyte Adhesion Deficiencies$243,282
R41 · FY2019 · AI · contact PI
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer$999,501
R42 · FY2018 · CA
Novel Use of Volatile Anesthetics as Topical Treatment for Painful Inflammatory Conditions: Interactions with Integrins and In Vivo Anti-inflammatory Effects.$223,735
R43 · FY2018 · AR
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer$313,705
R41 · FY2016 · CA
HTS platform for identification of regulators of cell adhesion molecule signaling$382,500
R01 · FY2014 · AI · contact PI
HTS platform for identification of regulators of cell adhesion molecule signaling$359,550
R01 · FY2013 · AI · contact PI
HTS platform for identification of regulators of cell adhesion molecule signaling$382,500
R01 · FY2012 · AI · contact PI